Advertisement
Advertisement
U.S. Markets open in 2 hrs 10 mins
Advertisement
Advertisement
Advertisement
Advertisement

Omeros Corporation (OMER)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.2200-0.2500 (-7.20%)
At close: 04:00PM EDT
3.1600 -0.06 (-1.86%)
After hours: 04:05PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.4700
Open3.4300
Bid3.0600 x 800
Ask4.5400 x 900
Day's Range3.1150 - 3.4300
52 Week Range1.8600 - 9.7800
Volume309,511
Avg. Volume1,027,236
Market Cap201.386M
Beta (5Y Monthly)0.72
PE Ratio (TTM)N/A
EPS (TTM)-2.4150
Earnings DateNov 07, 2022 - Nov 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.00
  • Benzinga

    Omeros COVID-19 Treatment Reduced Mortality Risk, But Biased Data Rendered Analysis Meaningless

    Omeros Corp (NASDAQ: OMER) reported results from the narsoplimab arm of the I-SPY COVID Trial, sponsored by Quantum Leap Healthcare Collaborative (QLHC). Narsoplimab showed the largest reduction in mortality risk to date across all drugs reported from the I-SPY COVID Trial. The company said that in approximately half of the patients died in the narsoplimab group, and narsoplimab was not given or was prematurely stopped, with those patients dying 9 to 35 days later. Omeros adds that despite narso

  • Business Wire

    Omeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID Trial

    SEATTLE, September 15, 2022--Omeros Corporation (Nasdaq: OMER) today reported results from the narsoplimab arm of the I-SPY COVID Trial, sponsored by Quantum Leap Healthcare Collaborative (QLHC). Analysis in the randomized patient population shows that the addition of narsoplimab to treatment of critically ill patients with COVID-19 reduces the mortality risk (hazard ratio [HR]=0.81, with probability [HR <1] equal to 0.77). Narsoplimab showed the largest reduction in mortality risk to date acros

  • Business Wire

    I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Reports Assessment of Narsoplimab for Treatment of Critically Ill Patients With COVID-19

    SAN FRANCISCO & SEATTLE, September 15, 2022--Quantum Leap Healthcare Collaborative (QLHC), sponsor of the I-SPY COVID Trial, and Omeros Corporation (NASDAQ: OMER), developer of the investigational agent narsoplimab, announced that enrollment has been closed and data have been analyzed in the narsoplimab arm of the I-SPY COVID Trial. The analysis in the randomized patient population, including those who declined treatment after randomization, shows that the addition of narsoplimab to treatment of

Advertisement
Advertisement